Gastrografin

Gastrografin is a brand-name, water-soluble iodinated contrast agent used in radiology to visualize the gastrointestinal tract. It contains diatrizoate meglumine and diatrizoate sodium in an aqueous solution and is considered hyperosmolar relative to body fluids. The contrast enhances radiographic imaging by increasing the density of the GI lumen, making mucosal outlines more conspicuous.

Indications for Gastrografin include imaging of the upper and lower GI tract and swallow studies, such as upper GI series, small bowel follow-through, and contrast-enhanced examinations. It is also used as an intestinal enema in colorectal imaging. Compared with barium, Gastrografin is preferred when there is a risk of perforation or leakage because, being water-soluble, it can be absorbed or excreted if extravasation occurs, reducing the risk of a persistent peritoneal reaction.

Administration and pharmacokinetics are procedure-dependent. Gastrografin is given orally or rectally, under clinical supervision, and the preparation remains within the lumen in patients with intact mucosa. If perforation or mucosal disruption occurs, some absorption may occur, and the agent is eventually eliminated by the kidneys. It is important to monitor fluid and electrolyte balance due to the agent’s hyperosmolar properties.

Contraindications include known allergy to iodinated contrast media and significant renal impairment or dehydration. Caution is advised in pregnancy and in individuals with a history of hypersensitivity to contrast agents. Adverse effects range from mild nausea and vomiting to more serious hypersensitivity reactions; osmotic diarrhea, abdominal cramps, and rare tissue irritation from extravasation can occur. Precautions with concomitant nephrotoxic drugs or metabolic conditions are advised.